Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) belong to the most common chronic inflammatory diseases (CIDs). While significant research efforts have led to improvements in treatment, ...
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, announced today the close of a $15 million Series A financing co-led by SPRIM ...
Knowing who may progress along the disease pathway is critical for early diagnosis and intervention, improved treatment and better disease management, according to a team that has developed a new ...